Encephalomyelitis is marked by inflammation of the brain and spinal cord that causes damage to the myelin- the protective sheath of nerve fibers. Dysfunction of the immune system makes the immune system wrongly attack healthy brain cells, which results in inflammation of the brain. Individuals having autoimmune encephalomyelitis can develop different neurological or psychiatric signs. In multiple sclerosis, the defensive insulation surrounding the nerve fibers- myelin gets damaged by the immune system, with scars remaining. Such damage makes the Central Nervous System (CNS) missed signals to the brain, resulting in an array of symptoms.
The biologically active compound found in the hemp plant, CBD, has several pharmacological effects. It is antioxidative, neuroprotective, anti-inflammatory, analgesic, antiemetic, and antipsychotic to name a few. The immunosuppressive and anti-inflammatory properties of CBD can be helpful in treating autoimmune disorders like multiple sclerosis and encephalomyelitis.
In this particular study, the beneficial utility of cannabinoids as novel interventional options for multiple sclerosis (MS) and associated neuropathic pain (NPP) is explored. Using an experimental autoimmune encephalomyelitis (EAE) animal model of MS, the therapeutic efficacy of two cannabinoid oil extract compositions (10:10 & 1:20 – tetrahydrocannabinol/cannabidiol) treatment. The findings of the research validated that cannabinoid therapy produces substantial improvement in neurological impairment scoring and behavioral evaluations of NPP that directly result from their capacity to decrease tumor necrosis factor alpha (TNF-alpha) production and promote brain-derived neurotrophic factor (BDNF) production. BDNF is a neurotrophin or a nerve growth agent vital for neuronal growth and survival, cognitive function and synaptic plasticity. It promotes motor neuron survival and axonal development of motor and sensory neurons. Dysregulation of BDNF signaling results in various neurodegenerative disorders like Alzheimer’s.
The above-mentioned study arrived at the following conclusions namely:
- Cannabinoid therapy causes improvements in neurological disability scoring
- Cannabinoid therapy also improves behavioral evaluations of neuropathic pain
- Cannabinoid therapy decreases TNF-alpha production and raises BDNF production
- EAE induction was responsible for the substantial reduction of 5hmC (5-hydroxymethylcytosine)
- The pharmacokinetic pattern of CBD oil extracts is examined which helps to know the way drugs flow across the body during distribution, metabolism, absorption, and excretion. Prior to exert any impact on the body, a drug has to be assimilated into the body processes.
Experimental Autoimmune Encephalomyelitis (EAE) is a well-recognized model of demyelinating diseases, like multiple sclerosis (MS). Similar to MS, EAE is distinguished by infiltration of immune cells into the central nervous system (CNS and demyelination. EAE is induced by two commonly used techniques namely, Active induction by immunization and Passive induction through adoptive transfer. The most prevalent mouse models of multiple sclerosis are Active immunization models where the mouse is immunized applying neuro antigens, like myelin antigens or spinal cord homogenate which results in the growth of active myelin-specific T cells, dispatching immune cells into the CNS, and immediate damage and inflammation of the central nervous system.
CBD Brings Multifarious Benefits In Multiple Sclerosis
In an autoimmune disorder, your immune system is unable to distinguish between healthy tissue and antigens. Under the circumstances, the body triggers a reaction that damages normal tissues. A demyelinating disease, Multiple Sclerosis (MS), affects the central nervous system and its symptoms are highly diverse but generally includes pain, fatigue, inflammation, spasticity, and depression. The analgesic, neuroprotective, anti-inflammatory and immunosuppressive qualities of CBD offers therapeutic help in managing the pain, spasticity, seizures, anxiety, muscle spasms and inflammation in MS.